Monday, February 23, 2026 — Investors are navigating a high-stakes premarket session this morning, driven by multi-billion dollar M&A activity in the biotech sector, disappointing clinical trial results from a pharmaceutical giant, and strong quarterly performance from a global fast-food leader.
Leading the charge is Arcellx (ACLX), which saw its valuation nearly double following an acquisition announcement by Gilead Sciences. Conversely, Novo Nordisk (NVO) is facing a significant sell-off after its next-generation obesity drug failed to meet key goals. Meanwhile, Domino’s Pizza (DPZ) is riding high on a combination of market share gains and a boosted dividend.
🚀 Arcellx (ACLX): Gilead Sciences Announces $7.8 Billion Buyout
The biotechnology sector is the center of attention this morning as Arcellx Inc. shares skyrocketed 78.3% in premarket trading. The surge follows a definitive agreement for Gilead Sciences (GILD) to acquire the company for $115 per share in cash, plus a contingent value right (CVR) that could add another $5 per share.
Key Terms of the Deal:
- Total Implied Value: Approximately $7.8 billion.
- Premium: The $115 cash offer represents a 68% premium over Arcellx’s 30-day volume-weighted average share price.
- Contingent Value: Shareholders may receive an additional $5 if cumulative global net sales of anito-cel reach at least $6 billion by the end of 2029.
- Closing Timeline: The transaction is expected to close in the second quarter of 2026.
The acquisition gives Gilead full control over anito-cel, a promising CAR T-cell therapy for multiple myeloma. The FDA has already accepted the Biologics License Application (BLA) for the drug, with a critical PDUFA action date set for December 23, 2026. This move effectively eliminates Gilead’s previous need to share profits and royalties with Arcellx, streamlining their oncology portfolio.
📉 Novo Nordisk (NVO): Shares Plunge on Trial Failure
In a sharp reversal for one of the market’s favorite weight-loss plays, Novo Nordisk shares tumbled as much as 14% in early trading. The volatility comes after the Danish pharmaceutical giant released data from its REDEFINE 4 trial.
The Trial Results:
The trial investigated CagriSema, a combined therapy intended to be the successor to the blockbuster Wegovy. While the drug delivered an impressive 23% weight loss in participants, it failed to achieve its primary endpoint of non-inferiority compared to rival Eli Lilly’s Zepbound in specific metrics.
This miss has reignited fears regarding the “extensive pricing headwinds” in the U.S. obesity market. Analysts note that while 23% weight loss is clinically significant, the failure to clearly outshine Eli Lilly’s current offerings has led some investors to reassess Novo Nordisk’s near-term growth trajectory. Despite the drop, the company continues its DKK 15 billion share buyback program, attempting to signal confidence to the market.
🍕 Domino’s Pizza (DPZ): “Hungry for MORE” Strategy Delivers
Domino’s Pizza shares climbed 5% premarket as the company reported a strong finish to fiscal 2025. The Ann Arbor-based chain outperformed analyst expectations across several key metrics, driven by its aggressive “Hungry for MORE” rebranding and digital upgrades.
Q4 and Fiscal 2025 Highlights:
- U.S. Same-Store Sales: Increased by 3.7%, beating estimates.
- Market Share: CEO Russell Weiner announced that Domino’s gained one full percentage point of market share over its QSR (Quick Service Restaurant) rivals last year.
- Dividend Boost: The Board of Directors approved a 15% increase to the quarterly dividend, now standing at $1.99 per share.
- Global Footprint: The company added 96 new stores in Q4, bringing its total global count to over 22,000 locations.
Investors are cheering the company’s ability to find growth in a mature category, particularly as both delivery and carryout segments showed resilience against broader inflationary pressures.
🔍 Other Notable Premarket Movers
| Symbol | Company | Move | Reason |
|---|---|---|---|
| WGS | GeneDx | 📈 +2% | Sustained momentum following positive analyst revisions. |
| ACHR | Archer Aviation | 📉 -4% | Technical pullback despite a “buy” rating and 90% upside target from Raymond James. |
| DFH | Dream Finders Homes | 📈 +1% | Inching higher ahead of housing data updates. |
| SCL | Stepan Co. | 📉 -3% | Trading lower following a disappointing earnings release. |
| FRPT | Freshpet | 📉 -1% | Slight retreat after a strong run-up last week. |
Market Summary
As the 9:30 AM ET opening bell approaches, the S&P 500 and Nasdaq-100 futures are showing mixed signals. While the biotech M&A provides a spark of optimism, the heavy weight of Novo Nordisk on the healthcare sector is keeping the broader indexes in check. Investors will be keeping a close eye on Gilead Sciences to see how the market reacts to its latest multibillion-dollar bet on the future of cancer treatment.
Would you like me to look up the full earnings transcripts for Domino’s Pizza or the detailed analyst reactions to the CagriSema trial results?